Melbourne, Australia, 29 October 2021 – Invetech, an end-to-end commercialization partner to world’s foremost therapeutic and diagnostic companies, has been named the Victorian Exporter of the Year at the 2021 Governor of Victoria Export Awards (GOVEA). Invetech also won the International Health category award.

The awards were introduced by Her Excellency the Honourable Linda Dessau AC, Governor of Victoria and the Honourable Martin Pakula MP, Minister for Trade during a virtual awards ceremony today.

The GOVEA are regarded as the most prestigious export awards in Victoria, Australia that acknowledge and reward the state’s most innovative exporters with the stamp of international success. The 2021 focus was on recognizing and rewarding ingenuity, excellence, innovation, creativity and leadership in international trade.

The Exporter of the Year award recognizes Invetech’s contribution to the international health sector through their product design and development services as well as their groundbreaking cell and gene therapy products and manufacturing solutions.

Invetech’s President Andreas Knaack said, “Over the last 30 years, but especially over the last 18 months, we have been fortunate to be able to leverage Victorian technology and knowhow for our international clients by creating solutions that detect COVID-19 and support the fight against cancer.”

“We are honored to receive the awards as acknowledgment of our export achievements. This is a great recognition for the entire Invetech team from Global Victoria and the Victorian Government,” he said.

In the diagnostic device market, Invetech’s approach to design, agile product development processes and product realization services delivers outstanding products that meet the most challenging clinical and business needs. In the cell and advanced therapy market, Invetech helps therapy developers accelerate life-changing therapies from the clinic to commercial-scale manufacturing.

Some of Invetech’s 2021 key achievements include the design and development of a diagnostic instrument and associated consumable for point of care molecular detection of infectious diseases, including COVID-19. On the cell and advanced therapy side, Invetech was selected by one of the world’s top five pharmaceutical companies to design and provide several machines for the commercialization of the company’s leading autologous cell therapy.

The GOVEA winners are automatically placed as finalists in the 59th Australian Export Awards. The national winners will be announced on Thursday 25 November 2021.

About Invetech:

For more than 30 years, Invetech has partnered with health and life science leaders around the world to co-create breakthrough solutions that millions rely on every day. Our mission is to expand the reach of next-generation healthcare by accelerating the design, engineering and manufacture of commercial-scale diagnostic products and vital therapies. As an end-to-end partner, we combine agile development, proven technology platforms and expert insights to bring clarity and speed to commercialization. Our collaborative, integrated approach resolves complexity and informs better decisions, ensuring high-quality products and therapies get to market with greater certainty, reliability and efficiency. Together, we are revolutionizing the future of healthcare.